Postdoctoral Fellows will:

• Design and execute an independent research project focused on cardiac or skeletal muscle biology
• Perform cutting-edge research under the direct mentorship of a Cytokinetics scientist and work in collaboration with other researchers throughout the company
• Have enrichment opportunities in communication, leadership, and laboratory management
• Gain foundational knowledge of the drug discovery and development process
• Cultivate a broad scientific network in biotech and academia

• Fully funded 2-year postdoctoral research fellowship
• Competitive salary
• Full benefits
• Funding for research conference travel (2 per year)

• PhD in biochemistry, bioengineering, cell/molecular biology, physiology, or related field
• Expertise in one or more of the following: primary and mammalian cell culture systems, in vivo models of heart failure and/or skeletal muscle diseases, NA-seq, proteomics, bioinformatics analysis
• Track record for research excellence, independent critical thinking, and the ability to design, execute, and interpret experiments as demonstrated by high quality publications, presentations, fellowship, and grants
• Enthusiasm for working in a team-based, multi-disciplinary environment, paired with excellent verbal and written communication skills
• Clear commitment to a rigorous 2-year research and enrichment program

• NIH Biosketch (formatting instructions can be found here)
• Cover letter (1-2 pages) that includes the following: (A) Summary of research accomplishments, (B) Proposed career path, (C) How a 2-year Cytokinetics postdoctoral fellowship will prepare you for your career path
• Three letters of recommendation

Effects of Omecamtiv Mecarbil in Heart Failure with Reduced Ejection Fraction According to Blood Pressure: The GALACTIC-HF Trial
European Heart Journal
Metra M, et al
May 22, 2022

A Novel Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics
Circulation: Heart Failure
He H, Baka T, Balschi J, et al
November 8, 2021

Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy
Journal of Medicinal Chemistry
Chihyuan Chuang, et al
Oct 4, 2021

GALACTIC-HF: Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
New England Journal of Medicine
Teerlink JR, Diaz R, Felker GM, McMurray JJ, Metra M, Solomon SD, Adams KF, Anand I, Arias‐Mendoza A, Biering‐Sørensen T, Böhm M, Bonderman D, et al.
November 13, 2020

Fast skeletal muscle troponin activator CK‐2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction
Journal of Physiology
Cheng AJ, Hwee DT, Kim LH, Durham N, Yang HT, Hinken AC, Kennedy AR, Terjung RL, JR Jasper, Malik FI, Westerblad H
June 29, 2017

The Small Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure
Journal of Pharmacology and Experimental Therapeutics
Hwee DT, Kennedy AR, Hartman JJ, Ryans J, Durham N, Malik FI, Jasper JR
April 2015

Activation of Fast Skeletal Muscle Troponin as a Potential Therapeutic Approach for Treating Neuromuscular Diseases
Nature Medicine
Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, Godinez G, Lee KH, Marquez D, Browne IV WF, Chen MM
March 2012

Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure
Science
Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R
March 2011